The “Transitional Coverage for Emerging Technologies” (TCET) offering is a slightly watered-down version of the reimbursement plan proposed earlier this year.
Marks the first & only blood test granted FDA marketing authorization for prognostication of disease progression in patients with advanced fibrosis due to NASH.
Axoft’s minimally invasive implants create a seamless interface with the nervous system, allowing ultra-high bandwidth and stable, single-neuron measurements.